Fig. 1: Molecular pathways amenable to therapeutic intervention in PTCL. | Modern Pathology

Fig. 1: Molecular pathways amenable to therapeutic intervention in PTCL.

From: Genetic profiling and biomarkers in peripheral T-cell lymphomas: current role in the diagnostic work-up

Fig. 1

Some of the available inhibitors are listed in red. Note that cerdulatinib is a dual SYK/JAK inhibitor. The gray boxes indicate specific vulnerabilities in distinct PTCL subtypes, and the oval circles contain some treatment related comments. ALK anaplastic lymphoma kinase, ALCL anaplastic large cell lymphoma, HSTL hepatosplenic T cell lymphoma, AILT angioimmunoblastic T cell lymphoma, DNMT DNA methyltransferase, HDAC histone deacetylase, ATLL adult T cell leukemia/lymphoma.

Back to article page